Northern Trust Corp Makes New $2.66 Million Investment in CeriBell (NASDAQ:CBLL)

Northern Trust Corp bought a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 102,828 shares of the company's stock, valued at approximately $2,661,000. Northern Trust Corp owned about 0.29% of CeriBell at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CBLL. Rhumbline Advisers purchased a new position in CeriBell during the fourth quarter worth about $320,000. Corebridge Financial Inc. acquired a new position in CeriBell during the 4th quarter worth approximately $158,000. PNC Financial Services Group Inc. purchased a new position in shares of CeriBell during the 4th quarter worth approximately $47,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of CeriBell in the 4th quarter valued at approximately $10,750,000. Finally, Vanguard Group Inc. purchased a new stake in shares of CeriBell in the fourth quarter valued at approximately $18,015,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $16.96, for a total value of $424,000.00. Following the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at $12,332,480.96. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 49,700 shares of company stock worth $796,434. 20.10% of the stock is owned by corporate insiders.

CeriBell Stock Performance

Shares of CBLL traded up $0.70 on Tuesday, reaching $17.28. The stock had a trading volume of 628,500 shares, compared to its average volume of 279,409. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The firm has a 50-day moving average of $17.06 and a 200 day moving average of $21.98.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. As a group, equities analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.